GlobeNewswire Inc.··Xenon Pharmaceuticals Inc.Xenon's Seizure Drug Azetukalner Shows Strong Phase 3 Results Ahead of 2026 FDA Filing
Xenon Pharmaceuticals reports positive Phase 3 data for azetukalner in focal onset seizures, with 53.2% seizure reduction versus 10.4% placebo. FDA submission planned for Q3 2026.
XENEPhase 3 clinical trialFDA approval